Los Angeles Capital Management
ALXN

Los Angeles Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Los Angeles Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,617
Closed -$400K – 1735
2021
Q1 		$400K Hold
2,617
– – ﹤0.01% 1314
2020
Q4 		$409K Sell
2,617
-130
-5% -$16.7K ﹤0.01% 1282
2020
Q3 		$314K Sell
2,747
-38,382
-93% -$4.14M ﹤0.01% 1260
2020
Q2 		$4.62M Buy
41,129
+3,703
+10% +$393K 0.02% 415
2020
Q1 		$3.36M Sell
37,426
-80
-0.2% -$7.85K 0.02% 414
2019
Q4 		$4.06M Hold
37,506
– – 0.02% 468
2019
Q3 		$3.67M Buy
37,506
+9,565
+34% +$1.08M 0.02% 478
2019
Q2 		$3.66M Sell
27,941
-1,370
-5% -$177K 0.02% 508
2019
Q1 		$3.96M Sell
29,311
-4,702
-14% -$585K 0.02% 481
2018
Q4 		$3.31M Sell
34,013
-24,733
-42% -$2.92M 0.02% 438
2018
Q3 		$8.17M Sell
58,746
-11,254
-16% -$1.41M 0.04% 368
2018
Q2 		$8.69M Sell
70,000
-10,818
-13% -$1.26M 0.05% 377
2018
Q1 		$9.01M Sell
80,818
-46,570
-37% -$5.57M 0.05% 334
2017
Q4 		$15.2M Buy
127,388
+50,162
+65% +$6.11M 0.08% 269
2017
Q3 		$10.8M Buy
77,226
+68,579
+793% +$9.32M 0.06% 300
2017
Q2 		$1.05M Sell
8,647
-76,941
-90% -$8.95M 0.01% 742
2017
Q1 		$10.4M Sell
85,588
-32,009
-27% -$4.13M 0.08% 293
2016
Q4 		$14.4M Sell
117,597
-1,093
-0.9% -$134K 0.11% 236
2016
Q3 		$14.5M Buy
118,690
+116,862
+6,393% +$15M 0.12% 232
2016
Q2 		$213K Hold
1,828
– – ﹤0.01% 1143
2016
Q1 		$254K Hold
1,828
– – ﹤0.01% 1001
2015
Q4 		$349K Hold
1,828
– – ﹤0.01% 947
2015
Q3 		$286K Sell
1,828
-1,660
-48% -$303K ﹤0.01% 1032
2015
Q2 		$631K Sell
3,488
-31
-0.9% -$5.35K 0.01% 884
2015
Q1 		$610K Sell
3,519
-400
-10% -$72.4K 0.01% 882
2014
Q4 		$725K Buy
3,919
+100
+3% +$18.5K 0.01% 734
2014
Q3 		$633K Buy
3,819
+1,890
+98% +$310K 0.01% 714
2014
Q2 		$301K Sell
1,929
-60,396
-97% -$9.54M ﹤0.01% 1028
2014
Q1 		$9.48M Buy
62,325
+60,525
+3,363% +$9.62M 0.1% 238
2013
Q4 		$239K Sell
1,800
-996
-36% -$120K ﹤0.01% 1165
2013
Q3 		$325K Sell
2,796
-23,307
-89% -$2.56M ﹤0.01% 1057
2013
Q2 		$2.41M Buy
+26,103
New +$2.52M 0.03% 423

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Los Angeles Capital Management's ALXN Position: Q2 2021 in Review

Los Angeles Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 2,617 shares — an estimated $400K sold.

Los Angeles Capital Management first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $15.2M in Q4 2017. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Los Angeles Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 2,617 Alexion Pharmaceuticals shares in Q2 2021, an estimated $400K.
  • Los Angeles Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • Los Angeles Capital Management's Alexion Pharmaceuticals position peaked at $15.2M in Q4 2017.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Los Angeles Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.